STD Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Sexually Transmitted Diseases (STD) Diagnostics Market Report is Segmented by Type of Disease (Chlamydia, Gonorrhea, Syphilis, Genital Herpes, Hepatitis B, HIV/AIDS (Human Immunodeficiency Virus Infection and Acquired Immune Deficiency Syndrome), Human Papillomavirus (HPV), and Other Diseases), Location of Diagnostic Test (Laboratory Testing and Point-Of-Care (PoC) Testing), Devices (Laboratory Devices and Point-Of-Care Devices), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers the Value (in USD) for the Above Segments.

STD Diagnostics Market Size

STD Diagnostics Market Summary
Study Period 2019 - 2029
Market Size (2024) USD 16.98 Billion
Market Size (2029) USD 23.91 Billion
CAGR (2024 - 2029) 7.08 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Medium

Major Players

STD Diagnostics Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Global STD Diagnostics Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

STD Diagnostics Market Analysis

The Global STD Diagnostics Market size is estimated at USD 16.98 billion in 2024, and is expected to reach USD 23.91 billion by 2029, growing at a CAGR of 7.08% during the forecast period (2024-2029).

Sexually transmitted diseases (STDs) are spread mainly by sexual contact. Sexually transmitted diseases (STIs) are caused by bacteria, viruses, or parasites. These STIs-causing microorganisms can be diagnosed by using STD diagnostics and help in receiving proper treatment. Factors such as the growing prevalence of STDs globally, growing government initiatives to create awareness about STDs, and increasing advancement in STD diagnostics are anticipated to drive the STD diagnostics market during the forecast period. The rising prevalence of STDs is expected to drive the market during the forecast period. For instance, the World Health Organization Report 2023 reported that more than 1.0 million sexually transmitted infections are acquired globally, and most of them are asymptomatic. It also reported that every year, there are an estimated 374.0 million new infections, with 1 out of 4 sexually transmitted infections: gonorrhea, chlamydia, trichomoniasis, and syphilis. Therefore, such an increasing prevalence and incidence rate of sexually transmitted diseases around the globe is expected to increase the demand for STD diagnostics, thereby propelling market growth during the forecast period. Also, the increasing government organizations' initiatives to create awareness about STDs are expected to increase the demand for STD diagnostics procedures for early detection of infections. For instance, in March 2022, the National Chlamydia Screening Program (NCSP) was organized in the United Kingdom. The major focus of this program was to reduce the harm of untreated chlamydia infection by primarily screening women and girls. In June 2022, the Centers for Disease Control and Prevention (CDC) recommended and issued guidelines for screening sexually transmitted diseases to create awareness toward screening programs for STDs and the increasing burden of STDs around the globe. Hence, such initiatives by government organizations are expected to drive the demand for the diagnosis of STDs, which is expected to drive the market during the forecast period. Also, advancements in STD diagnostics, research, and the development of new technologies are projected to fuel market growth. Also, the market is witnessing a major shift from conventional technologies to molecular diagnostics for the diagnosis of STDs, which is a breakthrough for the growth of the market. For instance, in May 2022, Medmira Inc. received a CE mark for its Multiplo complete syphilis (TP/nTP) antibody test (Multiplo TP/nTP). This approval enables the company to strengthen further its product offering in all markets that accept the CE mark. Hence, the rising prevalence of STDs, increasing government organizations' initiatives to increase awareness about STDs, and increasing product launches are expected to drive the STD diagnostic market. However, the social stigma associated with patients visiting specialized STD clinics and stringent regulatory scenarios for product approvals is expected to restrain the market during the forecast period.

STD Diagnostics Market Trends

The Laboratory Testing Segment is Expected to Witness Growth During the Forecast Period

Laboratory tests are the most common form of diagnosis of sexually transmitted diseases (STDs) around the globe. As laboratory tests are reliable and provide high accuracy, their usage is high, and people tend to trust laboratory tests more. The increasing prevalence of STDs is one of the factors for market growth. According to the July 2023 report from the World Health Organization, an estimated 39.0 million people were living with HIV at the end of 2022, with two-thirds of them residing in the WHO African Region. Thus, such a significant prevalence of STDs is expected to increase the demand for lab testing of such diseases. Continuous product launches have occurred in the field of molecular diagnostics, which is one of the leading factors responsible for the growth of the laboratory testing segment. More product launches allow laboratories to install instruments or equipment as needed. For instance, in May 2022, Qiagen Inc. launched NeuMoDxHSV 1/2 Quant Assay for the quantification and differentiation of herpes simplex virus type 1 (HSV-1) DNA and herpes simplex virus type 2 (HSV-2) with approval from the European Commission. The emergence of this assay allows the company to expand its product portfolio in laboratory testing, which ultimately helps market growth owing to the innovative tests. Additionally, in February 2023, Thermo Fisher Scientific launched TaqPath PCR kits in India for the identification of hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and genetic analysis (HLA B27). This launch is helping the company in broadening its diagnostics product market. Therefore, owing to the above-mentioned factors, such as the increasing prevalence of diseases and product launches, the laboratory testing segment is believed to witness high growth during the forecast period.

STD Diagnostics Market: Rates of HIV Diagnoses( In Percentage), European Region, 2022

North America is Estimated to Hold Significant Share in the Market During the Forecast Period

The sexually transmitted diseases diagnostics market is significant in North America, owing to the high prevalence of STDs in the region. The United States is expected to be the largest market in North America due to the presence of many diagnostic companies and increasing government initiatives to create awareness about STD disease awareness. The rising prevalence of STDs in North America is expected to drive the market during the forecast period. For instance, according to the Centers for Disease Control and Prevention STI Surveillance Report 2022, more than 2.5 million cases of chlamydia, gonorrhea, and syphilis were reported in the United States in 2022. The combined rate of infections from chlamydia, gonorrhea, and syphilis in 2022 was 751.6 cases per 100,000 people in the United States. Hence, the significant prevalence of STDs in the United States is expected to drive the market in North America during the forecast period. Also, the increasing government initiatives to create awareness about STDs are expected to increase the demand for the diagnosis of STDs at early stages to get appropriate treatment, which will ultimately drive the market during the forecast period. For instance, according to the Centers for Disease Control database (CDC), July 2023, in FY 2022, the United States Congress allocated USD 1.34 billion to CDC to prevent and control HIV, viral hepatitis, STIs, TB, infectious diseases, and the opioid epidemic, and promote adolescent and school health. Hence, this budget increased compared to the amount allocated to CDC in FY 2021, which was USD 1.31 billion. Therefore, increasing government investments to prevent and control STDs is expected to drive the market during the forecast period. Also, the increasing number of product launches is expected to drive the market during the forecast period. For instance, in May 2022, Abbott received the US FDA approval for its Alinity m STI Assay. This multiplex test can detect and differentiate four common STDs simultaneously. Hence, such product launches are expected to drive the STD diagnostic market in North America during the forecast period. Therefore, owing to the above factors, such as the rising prevalence of STDs, increasing government initiatives, and increasing product launches, they are expected to drive the growth of the STD diagnostics market in North America, which is expected to surge during the forecast period.

STD Diagnostics Market - Growth Rate by Region

STD Diagnostics Industry Overview

The market for STD diagnostics is semi-consolidated in nature. The key players are significantly involved in various strategic activities such as product launches, collaborations, and agreements to improve their global portfolios. A few of the key players in the STD diagnostics market are Abbott Laboratories, MedMira Inc., Qiagen Inc., Cepheid (Danaher Corporation), F. Hoffmann-La Roche AG, Diasorin SpA, bioMeriuex, Hologic Inc., and Bio-Rad Laboratories Inc.

STD Diagnostics Market Leaders

  1. Diasorin S.p.A

  2. Hologic, Inc

  3. Danaher Corporation(Cephied)

  4. Siemens Healthineers AG

  5. Abbott

*Disclaimer: Major Players sorted in no particular order

STD Diagnostics Market Concentration
Need More Details on Market Players and Competitors?
Download PDF

STD Diagnostics Market News

  • March 2023: The Centers for Disease Control and Prevention launched a Together TakeMeHome (TTMH) project to distribute up to 1 million free HIV self-tests over the next five years. People in the United States, including Puerto Rico, can order up to two free HIV self-tests every 90 days via an online portal.
  • February 2023: Mylab launched rapid tests such as PathoCatch HIV 1/2 AB test, PathoCatch HIV 1/2 AB test, and PathoCatch Syphilis AB test to identify sexually transmitted diseases such as HIV and syphilis.

Global STD Diagnostics Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Incidence and Prevalence Rates of STD

      2. 4.2.2 Implementation of National Screening Programs

      3. 4.2.3 Growing Innovations in the Development of STD Diagnostics

    3. 4.3 Market Restraints

      1. 4.3.1 Social Stigma Associated with Patients Visiting Specialized STD Clinics

      2. 4.3.2 Stringent Regulatory Scenario for Product Approvals

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD)

    1. 5.1 By Type of Disease

      1. 5.1.1 Chlamydia

      2. 5.1.2 Gonorrhea

      3. 5.1.3 Syphilis

      4. 5.1.4 Genital herpes

      5. 5.1.5 Hepatitis B

      6. 5.1.6 HIV/AIDS (Human immunodeficiency virus infection and acquired immune deficiency syndrome)

      7. 5.1.7 Human papillomavirus (HPV)

      8. 5.1.8 Other Diseases

    2. 5.2 By Location of Diagnostic Test

      1. 5.2.1 Laboratory Testing

      2. 5.2.2 Point-of-care (PoC) Testing

    3. 5.3 By Devices

      1. 5.3.1 Laboratory Devices

        1. 5.3.1.1 Thermal Cyclers - PCR

        2. 5.3.1.2 Lateral Flow Readers Immunochromatographic Assays

        3. 5.3.1.3 Flow Cytometers

        4. 5.3.1.4 Absorbance Microplate Reader - Enzyme Linked Immunosorbent Assay (ELISA)

        5. 5.3.1.5 Other Laboratory Devices

      2. 5.3.2 Point-of-care (PoC) Devices

        1. 5.3.2.1 Phone Chips (Microfluidics + ICT)

        2. 5.3.2.2 Portable/Bench Top/Rapid Diagnostic Kits

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Siemens Healthineers AG

      2. 6.1.2 Abbott

      3. 6.1.3 MedMira Inc

      4. 6.1.4 QIAGEN

      5. 6.1.5 Danaher Corporation (Cephied)

      6. 6.1.6 F. Hoffmann-La Roche Ltd

      7. 6.1.7 Diasorin SpA

      8. 6.1.8 BioMeriuex

      9. 6.1.9 Hologic Inc.

      10. 6.1.10 Bio-Rad Laboratories Inc.

      11. 6.1.11 BD

      12. 6.1.12 Thermo Fisher Scientific Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

STD Diagnostics Industry Segmentation

As per the scope of the report, STDs are infections that transmit from one person to another during oral, anal, and vaginal sex. Bacteria, parasites, yeast, and viruses are the main causes of STDs. Rapid and early diagnosis of STDs will limit the effects and progression of the disease. If the STDs are left untreated, they can lead to more serious and long-term health complications. The STD diagnostics market is segmented by type of disease, location of diagnostic test, device, and geography. By type, the market is segmented into chlamydia, gonorrhea, syphilis, genital herpes, hepatitis B, HIV/AIDS (human immunodeficiency virus and acquired immune deficiency syndrome), human papillomavirus, and other diseases. By devices, the market is segmented into laboratory devices (thermal cyclers - PCR, lateral flow readers immunochromatographic assays, flow cytometers, absorbance microplate reader - enzyme-linked immunosorbent assay (ELISA), and other laboratory devices) and point-of-care devices, phone chips (microfluidics + ICT), and portable/benchtop/rapid diagnostic kits). By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across significant global regions. The report offers the value (in USD) for the above segments.

By Type of Disease
Chlamydia
Gonorrhea
Syphilis
Genital herpes
Hepatitis B
HIV/AIDS (Human immunodeficiency virus infection and acquired immune deficiency syndrome)
Human papillomavirus (HPV)
Other Diseases
By Location of Diagnostic Test
Laboratory Testing
Point-of-care (PoC) Testing
By Devices
Laboratory Devices
Thermal Cyclers - PCR
Lateral Flow Readers Immunochromatographic Assays
Flow Cytometers
Absorbance Microplate Reader - Enzyme Linked Immunosorbent Assay (ELISA)
Other Laboratory Devices
Point-of-care (PoC) Devices
Phone Chips (Microfluidics + ICT)
Portable/Bench Top/Rapid Diagnostic Kits
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global STD Diagnostics Market Research Faqs

The Global STD Diagnostics Market size is expected to reach USD 16.98 billion in 2024 and grow at a CAGR of 7.08% to reach USD 23.91 billion by 2029.

In 2024, the Global STD Diagnostics Market size is expected to reach USD 16.98 billion.

Diasorin S.p.A, Hologic, Inc, Danaher Corporation(Cephied), Siemens Healthineers AG and Abbott are the major companies operating in the Global STD Diagnostics Market.

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).

In 2024, the North America accounts for the largest market share in Global STD Diagnostics Market.

In 2023, the Global STD Diagnostics Market size was estimated at USD 15.78 billion. The report covers the Global STD Diagnostics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global STD Diagnostics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.

Global STD Diagnostics Industry Report

Statistics for the 2024 STD Diagnostics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. STD Diagnostics analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.

close-icon
80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!

STD Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)